Drugs / autologous CMV-specific T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07546669 | Jan 2027 → Dec 2029 expected | glioblastoma | University Hospital, Essen | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous CMV-specific T-cells | “Based on patient-preference patients receive autologous CMV-specific T-cells additionally to vaccination contra herpes zoster after completion of radio(chemo-)therapy.” NCT07546669 ↗ |
| Modality | Cell therapy | “adoptive transfer of autologous polyclonal cytomegalovirus (CMV) specific T cells” NCT07546669 ↗ |
| Route | Intravenous | “Up to 6 intravenous infusions of in vitro-expanded T cells at a dose of 2 × 107 cells/m2 body surface area every 2 to 4 weeks shall be administered after clinical assessment.” NCT07546669 ↗ |